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The CXC chemokines have recently been identi®ed as a
family of molecules which can regulate angiogenesis.
Members of this family which contain the amino acid
motif Glu±Leu±Arg in their amino terminus (ELR+) act
as angiogenic factors, while ELR) members act as
angiostatic molecules. The balance of these angio-
genic versus angiostatic factors is critical in regulating
homeostasis. As we detail in this review, there is in-
creasing evidence from a variety of tumor model sys-
tems to suggest that the angiogenic members of this
family and their receptors may be playing an important
role in the neovascular pathology of solid tumors. In
contrast, the angiostatic effects of the ELR) family
members may provide novel therapeutic strategies for
treating many tumors. [Ó 1998 Kluwer Academic
Publishers]
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The angiogenic process
Angiogenesis is the growth of new blood vessels
from pre-existing vessels and capillaries. It is a
biological process that is critical to a variety of
physiological processes like embryogenesis and
wound repair. However, it is also a process which
can play a devastating role to the host in a number
of pathological processes such as chronic in¯am-
mation, ®broproliferative disorders and also tu-
morigenesis.1±9 The angiogenic response in the
microvasculature is associated with changes in
cellular adhesive interactions between adjacent
endothelial cells, pericytes and surrounding ex-
tracellular matrix.10±14 In the process of active
neovascularization, endothelial cells reorganize
their cytoskeleton, express cell surface adhesion
molecules such as integrins and selectins, secrete
proteolytic enzymes, and remodel their adjacent
extracellular matrix.15±23 These events are fol-
lowed by the formation of capillary buds. Auto-
crine and/or paracrine angiogenic factors must be
present to induce endothelial cell migration,
proliferation, elongation, orientation and differ-
entiation leading to the re-establishment of the
basement membrane, lumen formation and anas-
tomosis with other new or pre-existing vessels,
eventually leading to the formation of intact
microvessels.18,24,25 If there is a preponderance of
angiogenic factors in the local milieu, the neo-
vasculature may persist as capillaries, or differen-
tiate into mature venules or arterioles. If instead,
the local milieu changes such that there is a pre-
ponderance of angiostatic factors, the neovessels
can regress. The angiostatic factors which mediate
regression can do so either by inducing apoptosis
or cell cycle arrest of endothelial cells.20,26,27 Thus
the process of angiogenesis is regulated by a
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complex balancing act between opposing angio-
genic and angiostatic factors.
CXC chemokines
There have been a number of important angio-
genic regulators described.2,9 Perhaps the best
studied of the angiogenic factors have been the
molecules vascular endothelial growth factor
(VEGF)28,29 and basic ®broblast growth factor
(bFGF).30 In addition, angiostatin has been
widely studied as an inhibitor of angiogenesis.31
While there is no debating the importance of
these factors in certain physiological processes
(e.g. during embryogenesis), as well as during
tumorigenesis, there is growing evidence that
other angiogenic factors also play relevant roles. In
1992, a member of the CXC chemokine family,
interleukin-8 (IL-8), was shown to be an angio-
genic factor.32±34 As will be discussed in this re-
view, more recent work has shown that members
of the CXC chemokine family can be divided into
both promoters of angiogenesis, as well as inhib-
itors of angiogenesis. Chemokines can be made by
all nucleated cells in the body, which makes them
good candidates to be involved in a wide variety of
different solid tumors.35±48
The human CXC chemokine family consists of
chemotactic polypeptides that are less than 10 kDa
and are characteristically heparin binding proteins.
On the structural level, this family displays four
highly conserved cysteine amino acid residues,
with the ®rst two cysteines separated by one non-
conserved amino acid residue, hence the name
CXC.34±43 Although the CXC motif distinguishes
this family from other chemokine families, a sec-
ond structural domain within the CXC family
members dictates their angiogenic potential (see
below). The amino-terminus of the majority of the
CXC chemokines contains three amino acid resi-
dues (Glu±Leu±Arg: the ELR motif) which preceed
the ®rst cysteine amino acid residue of the primary
structure of these chemokines.35±44 In general,
those family members which contain the ELR
motif have enhanced neutrophil binding capabili-
ties and are angiogenic. In contrast, those members
which do not contain the ELR motif are angio-
static. Table 1 lists some of the CXC chemokine
family members which have been identi®ed and
separates them into whether they are angiogenic
(ELR+) or angiostatic (ELR)) (reviewed else-
where35±37,39,44,49). The angiogenic members in-
clude IL-8, epithelial neutrophil activating
protein-78 (ENA-78), growth related genes
(GRO-a, -b and -c), granulocyte chemotactic
protein-2 (GCP-2) and platelet basic protein (PBP)
as well as its amino-terminal truncated forms
which are generated by proteolytic cleavage with
monocyte-derived proteases and include connective
tissue activating protein-III (CTAP-III), b-
thromboglobulin (b-TG) and neutrophil activat-
ing protein-2 (NAP-2).50 GRO-a, -b and -c are
closely related CXC chemokines, with GRO-a
originally described for its melanoma growth
stimulatory activity.51±53 IL-8, ENA-78 and GCP-
2 were all initially identi®ed on the basis of neu-
trophil activation and chemotaxis.35±44
The angiostatic members include platelet
factor 4 (PF4), which was originally described
Table 1. The ELR+ and ELR) CXC chemokines, and their re-
sponses in the corneal micropocket model of angiogenesis
when tested alone or in combination
















IL-8 + IP-10 )
IL-8 + MIG )
ENA-78 + IP-10 )
ENA-78 + MIG )
bFGF + IP-10 )
bFGF + MIG )
VEGF + IP-10 )
VEGF + MIG )
In addition, the effect of the ELR) CXC chemokines was tested
on bFGF- and VEGF-induced angiogenesis. ND means not
done in these experiments. In addition, the chemokines which
score postitive in the CMP assay have also been determined to
directly cause endothelial cell chemotaxis and proliferation.
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for its ability to bind heparin and inactivate
heparin's anticoagulation function.54 Other ELR),
angiostatic CXC chemokines include monokine-
induced by interferon-c (MIG),43 interferon-c-
inducible protein (IP-10)43 and stromal
cell-derived factor (SDF-1). SDF-1 recently gained
notoriety when it was shown that SDF-1 induces
lymphocyte migration and prevents infection of T
cells by lymphotropic strains of HIV-1.43±48,55±67
Despite the name, IP-10 can be induced by all
three interferons (IFN-a, -b and -c), while MIG is
unique in that it is only induced by IFN-c. 43±48,
55±67 Interestingly, although IFN-c induces the
production of the angiostatic molecules IP-10 and
MIG, it attenuates expression of the angiogenic
molecules IL-8, GRO-a and ENA-78.68,69 This
differential regulation of angiostatic versus an-
giogenic CXC chemokines by IFN-c is likely to
account for the previously documented angiostatic
effects of IFN-c on wound repair-associated an-
giogenesis.2±4,70
While numerous in vivo and in vitro inv-
estigations have shown the importance of CXC
chemokines in in¯ammation as chemotactic/acti-
vating factors for neutrophils and mononuclear
cells, only recently has it become apparent that
these CXC chemokines are important in the reg-
ulation of angiogenesis.
CXC chemokines are potent regulators
of angiogenesis
In 1982, Taylor showed that PF4 could produce
an avascular zone when tested in a chorioallantoic
membrane (CAM) assay.71 In 1990, Maione and
his colleagues had demonstrated that recombinant
human PF4 (an ELR) CXC chemokine) could
inhibit angiogenesis, and cause growth inhibition
of melanoma and colon carcinomas.71±74 While
these were the ®rst documented results showing
that CXC chemokines could negatively regulate
angiogenesis, it was not until 1992 that it was
discovered that CXC chemokines could also pos-
itively mediate angiogenesis. IL-8, an ELR+ CXC
chemokine, was shown to be able to mediate both
in vitro endothelial cell chemotactic and prolifer-
ative activity, as well as in vivo angiogenesis in the
absence of preceding in¯ammation using bioassays
of angiogenesis.32±34 These experiments proved
that IL-8 was having a direct effect on the endo-
thelial cells and that this angiogenic activity was
distinct from its ability to recruit neutrophils.
These ®ndings suggested that members of the
CXC chemokine family function in a disparate
manner and can behave as either potent angio-
genic or angiostatic factors in regulating net
neovascularization.
Based on these ®ndings, we hypothesized that
the `ELR motif' of members of the CXC chemo-
kine family is a structural/functional domain that
dictates their angiogenic activity. To test this
postulate, endothelial cell chemotaxis was per-
formed in the presence or absence of varying
concentrations of ELR+ (IL-8 and ENA-78) or
ELR) CXC chemokines (PF4 and IP-10) to as-
certain whether CXC chemokines display dispa-
rate angiogenic activity. Both IL-8 and ENA-78
demonstrated a dose-dependent increase in endo-
thelial migration with an EC50 of 5 nM.
49 In
contrast, neither PF4 nor IP-10 induced signi®-
cant endothelial cell chemotaxis.49 Other CXC
chemokines were tested for their ability to induce
endothelial cell migration, including ELR+ CXC
chemokines GCP-2, GRO-a, GRO-b, GRO-c,
PBP, CTAP-III and NAP-2 or the ELR) CXC
chemokine MIG. All of the ELR+ CXC chem-
okines tested demonstrated signi®cant endothelial
cell chemotactic activity over background,
whereas the endothelial cell chemotactic activity
of MIG was similar to either PF4, IP-10 or
background.49 These studies established that
CXC chemokines can be divided into two major
groups (ELR+ and ELR)) with de®ned biological
activities.
To con®rm that PF4, IP-10 and MIG are in-
hibitors of angiogenesis, endothelial cell chemo-
taxis was performed in response to ELR+ CXC
chemokines (IL-8 or ENA-78) or bFGF with or
without varying concentrations of PF4, IP-10 or
MIG. The ELR) CXC chemokines (PF4, IP-10 or
MIG) signi®cantly inhibited endothelial cell mi-
gration in response to either the ELR+ CXC
chemokines or bFGF with an IC50 ranging from
50 pM to 1 nM.49 In contrast to their ability to
attenuate endothelial cell migration, neither IP-
10 nor MIG inhibited IL-8-induced neutrophil
chemotactic activity.49
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These in vitro studies were extended to an in
vivo angiogenesis bioassay. ELR+ CXC chem-
okines (IL-8, ENA-78, GRO-a or GCP-2), bFGF
or VEGF, either alone or in combination with
ELR) CXC chemokines (IP-10 or MIG) were
implanted into a rat cornea using the cornea
micropocket assay (CMP) of neovascularizat-
ion.49,76,77 The ELR+ CXC chemokines (IL-8,
ENA-78, GRO-a or GCP-2), bFGF or VEGF
induced positive corneal angiogenic responses,
whereas both IP-10 and MIG failed to induce a
neovascular responses in the CMP. When com-
bined with the ELR+ CXC chemokines (IL-8,
ENA-78, GRO-a or GCP-2), bFGF or VEGF, IP-
10 markedly abrogated the ELR+ CXC chemo-
kine, bFGF, or VEGF-induced angiogenic re-
sponse. Furthermore, MIG and SDF-1 similar to
IP-10, inhibited IL-8-, ENA-78-, bFGF- and
VEGF-induced corneal neovascularization (Ta-
ble 1). The fact that both the ELR+ and ELR)
CXC chemokines exerted their angiogenic or an-
giostatic effects, respectively, in the absence of
cellular in®ltration again suggests that the ability
to modulate angiogenesis is independent of the
role these molecules play as leukocyte chemoat-
tractants.
To establish that the `ELR motif' is the critical
structural/functional domain that dictates angio-
genic activity for members of the CXC chemokine
family, site-directed mutants were constructed
that contained either TVR (from IP-10) or DLQ
(from PF4) amino acid residue substitutions for
the `ELR motif' of wild-type IL-8.49 In addition a
site-directed mutant of MIG was produced, con-
taining the `ELR motif' immediately adjacent to
the ®rst cysteine amino acid residue of the pri-
mary structure of MIG.49 Endothelial cell
chemotaxis was used to assess the biological ac-
tivity of these muteins. Both IL-8 mutants failed
to induce endothelial cell migration; however,
both mutants inhibited the maximal endothelial
chemotactic activity of wild-type IL-8.49 Ex-
tending these studies to the CMP assay, both IL-8
muteins also inhibited the angiogenic response of
either wild-type IL-8 or ENA-78.49 In addition,
both mutants inhibited bFGF-induced angiogenic
activity in the CMP assay.49 In contrast, the ELR+
mutant of wild-type MIG induced a signi®cant
angiogenic response and wild-type MIG inhibited
the angiogenic response of this mutant in the
CMP assay.49 These studies support the conten-
tion that the `ELR' motif of CXC chemokines is
the important structural/functional domain that
dictates the angiogenic activity of CXC chem-
okines. Furthermore, these ®ndings support the
contention that ELR) CXC chemokines are po-
tent inhibitors of not only ELR+ CXC chem-
okines, but also the unrelated angiogenic factors,
bFGF and VEGF, a fact which could prove to be
very useful therapeutically.
ELR+ CXC chemokines regulate
tumorigenesis
Folkman was the ®rst to popularize the idea that
tumors cannot grow beyond the size of 2 mm3 in
the absence of neovascularization and delivery of
oxygen and nutrients.1,4,78,79 Tumor-associated
vascular mass can show as much as a 400% in-
crease over normal tissue vascular mass.4 Clearly
then, an imbalance in the production of angio-
genic, as compared to angiostatic, factors con-
tributes to the pathogenesis of all solid tumor
growth. Moreover, a number of studies have de-
termined that the magnitude of tumor-derived
angiogenesis is directly correlated with their
metastatic potential.80±86 This suggests that tu-
mor-associated angiogenesis is somehow disregu-
lated to allow the unchecked over-expression of
the angiogenic factors or perhaps the inappropri-
ate suppression of angiostatic ones.4,87,88 Mem-
bers of the CXC chemokine family have now been
shown to be important regulators of tumorigen-
esis in many different tumor model systems.
IL-8 has been found to be signi®cantly elevated
in non-small cell lung cancer (NSCLC).88 In
addition, IL-8 was determined to be a major
angiogenic factor contributing to overall tumor-
derived angiogenic activity in NSCLC.89,90 These
studies were extended to an in vivo model system
of human tumorigenesis, which employed a hu-
man NSCLC/SCID mouse chimera by injecting
human NSCLC cell lines into SCID mice.90 This
model system demonstrated a progressive increase
in tumor size that was directly correlated with
tumor-derived IL-890 in both tumor homogenates
and plasma. Interestingly, the histology of these
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126 Angiogenesis á Vol 2 á No 2 á 1998
tumors demonstrated a paucity of in®ltrating
neutrophils despite an appropriate neutrophil
chemotactic signal and the ability of murine
neutrophils to respond to human IL-8.91 The lack
of tumor neutrophil in®ltration is similar to the
previous observation of IL-8 in association with
freshly isolated human NSCLC tumors.89 This
paucity of neutrophils is probably best explained
by the fact that high circulating levels of IL-8
diminish the ability of the neutrophils to sense a
chemotactic gradient leading to the site of local
production. This simulates the phenomenon re-
cently described in the IL-8 transgenic mouse.91
In these mice, human IL-8 overexpression is as-
sociated with increased circulating levels of IL-8,
similar to what we have observed in the human
NSCLC/SCID mice during tumorigenesis. The
high circulating IL-8 levels correlated with a
proportional decrease in L-selectin expression on
neutrophils.91 The IL-8 transgenic mice demon-
strated a defect in neutrophil recruitment to the
peritoneal cavity after i.p. injection of either ex-
ogenous IL-8 or thioglycollate.91 The IL-8 trans-
genic mouse model exempli®es the importance of
localized production of IL-8 in order to establish a
chemotactic gradient and target leukocytes to
sites of in¯ammation. Accordingly, our study es-
tablishes a potential mechanism whereby the tu-
mor may evade an innate host response by
releasing suf®cient IL-8 into the circulation and
attenuating neutrophil extravasation at the site of
the tumor, yet at the same time promoting tu-
mor-derived angiogenesis.
To ascertain whether IL-8 contributes to tu-
morigenesis of human NSCLC in SCID mice,
animals were subjected to a strategy of IL-8 de-
pletion. Tumor-bearing animals were either pas-
sively immunized with either neutralizing IL-8 or
control antibodies, or not treated. Tumor-bearing
animals treated with neutralizing antibodies to
IL-8 demonstrated a greater than 40% reduction
in tumor growth, that was paralleled by a re-
duction in spontaneous metastases to the lung.90
To determine the mechanism of tumor growth
inhibition, ex vivo angiogenic activity was evalu-
ated from NSCLC tumor homogenates from ani-
mals that had been treated in vivo with either
control or neutralizing anti-IL-8 antibodies.
Eighty-®ve percent of tumor samples from control
antibody-treated animals induced positive corneal
angiogenic responses. In contrast, less than 33%
of tumor samples from anti-IL-8-treated animals
induced a positive corneal neovascular response.
The decreased angiogenic activity also correlated
with a reduction in tumor vessel density. These
studies demonstrated that a primary angiogenic
signal for NSCLC neovascularization in vivo was
directly mediated by tumor-associated IL-8.
ELR) CXC chemokines regulate
tumorigenesis
In an analogous manner, the angiostatic molecule
IP-10 was shown to be an endogenous inhibitor of
tumor formation. Squamous cell carcinomas,
which in general are very slow growing lung can-
cers and grow poorly when xenotransplanted to
SCID mice, were shown to have high endogenous
levels of IP-10.92 If a neutralizing antibody to IP-
10 was given during the course of squamous cell
tumor growth (modeled by injecting Calu 1 cells
into SCID mice), tumor formation was increased.92
Conversely, if recombinant IP-10 was given re-
peatedly to SCID mice injected with the aggressive
A549 adenocarcinoma cell lines, tumor growth
could be diminished by as much as 40%. The
mechanism of growth inhibition by intratumor
administration of recombinant human IP-10 was
found to be correlated with a reduction in primary
tumor-derived angiogenic activity and neovascu-
lature. These studies demonstrate the existence of
an imbalance in the over- and under-expression of
angiogenic and angiostatic CXC chemokines, res-
pectively, during tumorigenesis of NSCLC.
In a similar manner, work from Luan et al. has
shown that GRO-a and -c are critical oncogenic
factors for melanoma.93 This group was able to
show by both message level and protein produc-
tion, the expression of GRO-a in 70% of human
melanoma lesions examined. Interestingly,
immunohistochemical analysis revealed that
GRO-a expression, as well as the expression of the
putative GRO-a receptor (CXCR2) was present in
both the tumor cells as well as the tumor-in®l-
trating endothelial cells of the microvessels in
seven of the 11 tumors studied.93 The biological
consequence of this constitutive overexpression
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was tested by transfecting the GRO-a, -b or -c
genes into mouse melan-a melanocytes, resulting
in nearly 100% tumor formation when these
clones were injected into SCID or Nude mice. In
contrast, appropriate vector control transfections
yielded tumors below 10% of the time. Further-
more, polyclonal antisera to GRO-a and -c re-
duced tumor growth in the GRO-a and -c
transfected melan-a melanocyte tumor models,
respectively.92 Conditioned media from both the
transfected cells was able to induce a neovascular
response in the CMP assay of angiogenesis and, as
expected, antibodies against these angiogenic
CXC chemokine molecules inhibited this re-
sponse, clearly implicating the overexpression of
the GRO-a and -c chemokines, as positive regu-
lators of angiogenesis, in the pathogenesis of
melanoma. This group went on to suggest a
mechanism by which melanoma cells might be
turning on the constitutive overexpression of the
GRO chemokines.92 In Hs294T melanoma cells,
the half-life of the IjB protein is shortened in
comparison to normal retinal epithelial cells. This
results in constitutive NFjB localization to the
nucleus in these cells. The authors propose that
this constitutive NFjB activation, in concert with
other constitutively active transcription factors
(i.e. the 115 kDa IUR-binding factor), promotes
constitutive expression of the GRO genes, re-
sulting in an imbalance in the local production of
angiogenic versus angiostatic factors. As one
might predict, the expression of the angiostatic
CXC chemokine IP-10 was very low in this sys-
tem.93
Kitadai et al., working with human gastric
carcinomas, examined IL-8 mRNA by Northern
blot, in situ mRNA hybridization and IL-8 pro-
tein by ELISA in eight human gastric carcinoma
cell lines and 39 gastric carcinomas.94 High levels
of IL-8 were found in six of eight gastric carci-
noma cell lines and 32 of 39 gastric carcinoma
specimens, as compared to normal mucosa control
specimens. The levels of IL-8 in the neoplasms
strongly correlated with the vascularity of the
specimens as determined by vessel counting using
antibodies to CD34 (r  0.812, p  0.001).94
These data suggest that IL-8 produced by gastric
tumor cells may regulate neovascularization, and
hence the growth and metastasis of gastric carci-
noma. In addition, Lingen et al. have demon-
strated that IL-8 is the major inducer of
neovascularization produced by oral squamous cell
carcinomas.95
Finally, our unpublished observations working
in a SCID model of human prostate cancer anal-
ogous to the one described above for NSCLC have
shown that IL-8 is a positive regulator of tumor
formation in SCID mice injected with the prostate
cancer cell line PC-3. Conditioned media from
this cell line is angiogenic in the CMP assay of
angiogenesis and this activity is blocked in the
presence of neutralizing antibody to IL-8. Fur-
thermore, injection of neutralizing antibody to IL-
8 reduced the growth of PC-3 tumors in SCID
mice by 50%. In a similar manner, studies using
another prostate cancer cell line, Du145 have
shown that GRO-a, not IL-8, is the predominant
CXC chemokine which regulates angiogenic ac-
tivity in the CMP assay of angiogenesis. These
studies highlight the fact that even within a
particular type of tumor, different members of the
CXC chemokine family can regulate angiogenic
potential and tumorigenicity.
One important observation to note is that the
ELR+ CXC chemokines can exert their effect di-
rectly on the endothelial cells themselves. In vitro
chemotaxis assays and the CMP assays all dem-
onstrate that IL-8, ENA-78, GCP-2, PBP, CTAP-
III, NAP-2, and GRO-a, -b and -c have direct
proliferative and chemotactic activities on the
endothelial cells themselves.49 Although GRO-a
and -c have been shown to be mitogenic for
melanoma cells,92 in the case of NSCLC and
prostate cancer, we have clearly shown that the
CXC chemokines are not having autocrine pro-
liferative effects on the tumor cells themselves.
Chemokine receptors regulate
angiogenesis
As mentioned earlier, the chemokines can be
made by all nucleated somatic cells, and the re-
ceptors for these CXC chemokines have been
cloned and identi®ed to have speci®c ligand±
receptor pro®les. For example, IL-8 speci®cally
binds to CXCR1, ELR+ CXC chemokines bind to
CXCR2, IP-10 and MIG (ELR) CXC chem-
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okines) bind to CXCR3, and SDF-1 binds to
CXCR4 (Table 2).44,96,97 Evidence suggests that
the endothelial receptor for ELR+ CXC chem-
okines is the CXC chemokine receptor 2, CXCR2.
In support of this concept is the following infor-
mation: (1) both IL-8 and NAP-2 (ELR+ CXC
chemokines) have been shown to bind endothelial
cells,97 (2) CXCR2 is the putative receptor for all
ELR+ CXC chemokines on neutrophils42,98 and
all ELR+ CXC chemokines are angiogenic,49 (3)
while the Duffy antigen receptor for chemokines
(DARC) has been identi®ed on post-capillary ve-
nule endothelial cells,101 this receptor binds not
only ELR+ CXC chemokines, but also a variety of
CC chemokines without apparent signal-cou-
pling,101 (4) expression of CXCR2 in human burn
wound (granulation tissue) is found in association
with capillary endothelial cells in areas of ne-
ovascularization,102 (5) expression of CXCR2 in
human melanoma is associated with both mela-
noma cells and microvessels within the tumor,93
and (6) recent ®ndings from our laboratory have
demonstrated that neutralizing antibodies to
murine CXCR2 attenuate the angiogenic activity
of murine KC (a structural and functional ho-
molog of human GRO-a), murine MIP-2 (a
structural and functional homolog of human
GRO-b and-c) and human IL-8 in the rat CMP
bioassay, without inhibiting the angiogenic ac-
tivity of either bFGF or VEGF (unpublished ob-
servation). While these observations support the
notion that CXCR2 may be the receptor which
mediates ELR+ CXC chemokine-mediated an-
giogenesis, perhaps the most compelling evidence
comes from the recent work studying the viral
etiology of the extremely vascular angiosarcoma,
Kaposi's sarcoma.103±107
In 1994, Chang et al. discovered the Kaposi's
sarcoma associated herpesvirus (KSHV or HHV-
8).108 This virus has been detected in every Ka-
posi's sarcoma biopsy, and is implicated in the
pathogenesis of both Kaposi's sarcoma and of
primary effusion B cell lymphomas (PELs).108±113
The virus infects malignant and progenitor cells
in these lesions, and encodes a number of putative
oncogenes believed to be involved in the angio-
genic pathogenesis of these diseases. ORF 74 of
KSHV encodes a G-protein-coupled receptor
(KSHV-GPCR) that stimulates signaling path-
ways leading to cell proliferation in a constitutive,
agonist-independent manner.103,104 KSHV-
GPCR is most homologous to the human recep-
tor for the angiogenic chemokine IL-8 or
CXCR2.103,104 Work by Bais et al. demonstrated
that signaling through this KSHV-GPCR leads to
transformation and tumorigenicity. They dem-
onstrate that this constitutively active receptor
activates two protein kinases, JNK/SAPK and
p38MAPK, and triggers signaling cascades simi-
lar to in¯ammatory cytokines. Speci®cally, they
suggest that the production of the transcription
factor AP-1 leads to the activation and secretion of
VEGF, which may in turn increase the angiogenic
potential of the tumor.104 Of interest, however, is
that the IL-8 promoter is also strongly positively
regulated by AP-1 (our unpublished observa-
tions)40,112 and it would be interesting to see if
constitutive activation of this `CXCR2-like' re-
ceptor leads to the autocrine production of ELR+
CXC chemokines. Regardless, the fact that a
constitutively active CXCR2-like receptor has
been pirated by a virus that induces an angiosar-
coma supports the notion that CXCR2 is likely to
be the `angiogenic' receptor on endothelial cells
and suggests that this might be an important
therapeutic target to treat vascular neoplasms.
IP-10 appears to bind to a speci®c cell surface
site on endothelial cells.26 This receptor appears to
be a heparin sulfate proteoglycan associated re-
ceptor, as either heparin together with IP-10 or
heparinase pretreatment of endothelial cells atten-
uates IP-10 binding.26 This binding site is speci®c
for IP-10, as neither ELR+ CXC chemokines nor
various CC chemokines compete for binding on





CXCR1 CXCR2 CXCR3 CXCR4
IL-8 + + ) )
ENA-78 )a + ) )
GRO-a )a + ) )
IP-10 ) ) + )
MIG ) ) + )
SDF-1 ) ) +b +
a Low-af®nity binding.
b Unpublished observation
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this site. Furthermore, binding of IP-10 to endo-
thelial cells results in inhibition of proliferation
independent of calcium ¯ux and apoptosis, and
dependent on reversible cell cycle arrest.26 It is not
clear if this receptor represents the recently
identi®ed receptor for IP-10/MIG (CXCR3) ex-
pressed on T cells.96 These ®ndings suggest that
IP-10 and potentially MIG are unique members of
the CXC chemokine family that share a heparin
sulfate proteoglycan component of their receptor
that accounts for their binding to endothelial cells
and subsequent angiostatic activity.
Conclusion
Angiogenesis is regulated by an opposing balance
of angiogenic and angiostatic factors. The above
studies have demonstrated that as a family, the
CXC chemokines behave as either angiogenic or
angiostatic factors, depending on the presence of
the `ELR motif' that immediately precedes the
®rst cysteine amino acid residue of the primary
structure of these cytokines. Moreover, CXC
chemokines appear to be important endogenous
factors that regulate angiogenesis in association
with tumorigenesis in a number of different
neoplasms. These ®ndings support the notion that
therapy directed at either inhibition of angiogenic
or augmentation of angiostatic CXC chemokine
biology may be a novel approach in the treatment
of solid tumors.
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